Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Cellulitis, Vaccination site erythema, Vaccination site mass, Vaccination site pruritus, Vaccination site warmth
Clinical narrative: Hot; Kind of a knot; Itched; Red at injection site; Cellulities type reaction; This spontaneous case was reported by a consumer and describes the occurrence of CELLULITIS (Cellulities type reaction) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039K20A and 013M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Drug allergy (Clindamycin), Drug allergy (Levaquin), Atrial fibrillation paroxysmal, Coronary artery stenosis (Cardiac Stenosis, Bilateral), Chronic fatigue, Peripheral arterial disease, Atrial fibrillation since 05-Jan-2021 and Parkinson's disease. Concomitant products included APIXABAN for Clot blood, AMANTADINE, ATORVASTATIN, FUROSEMIDE and DILTIAZEM for an unknown indication.   On 13-Jan-2021 at 5:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Feb-2021 at 5:15 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 21-Jan-2021 at 9:00 AM, the patient experienced CELLULITIS (Cellulities type reaction) (seriousness criterion medically significant). On 25-Jan-2021, the patient experienced VACCINATION SITE WARMTH (Hot), VACCINATION SITE MASS (Kind of a knot), VACCINATION SITE PRURITUS (Itched) and VACCINATION SITE ERYTHEMA (Red at injection site). The patient was treated with HYDROCORTISONE for Vaccination site pruritus, at a dose of 1 UNK; Manual therapy (Cold compresses) for Cellulitis; Manual therapy (Cold compresses) for Vaccination site warmth; Manual therapy (Cold compresses) for Vaccination site mass; Manual therapy (Cold compresses) for Vaccination site pruritus and Manual therapy (Cold compresses) for Vaccination site erythema. On 02-Feb-2021, CELLULITIS (Cellulities type reaction) had resolved. At the time of the report, VACCINATION SITE WARMTH (Hot), VACCINATION SITE MASS (Kind of a knot), VACCINATION SITE PRURITUS (Itched) and VACCINATION SITE ERYTHEMA (Red at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered CELLULITIS (Cellulities type reaction) to be related. No further causality assessments were provided for VACCINATION SITE WARMTH (Hot), VACCINATION SITE MASS (Kind of a knot), VACCINATION SITE PRURITUS (Itched) and VACCINATION SITE ERYTHEMA (Red at injection site).    Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   Most recent FOLLOW-UP information incorporated above includes: On 02-Jul-2021: Follow up ADR form received: Updated patient details, concomitant medication, second  vaccine details, event changed to potentially serious and outcome of event were added.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.